Navigation Links
Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Date:7/2/2008

elp mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is in two Phase II combination therapy trials for the treatment of metastatic breast cancer and for the treatment of non-small cell lung cancer (NSCLC). A second Phase II combination therapy study in breast cancer patients is expected to begin soon. Data presented at the 2008 ASCO annual meeting showed that half of evaluable patients in a Phase Ib trial of bavituximab plus chemotherapy achieved an objective tumor response or stable disease after eight weeks of dosing, that the safety profile of bavituximab and chemotherapy appeared consistent with chemotherapy alone and that the pharmacokinetic properties of bavituximab were not affected by co-administration with conventional chemotherapies. A Phase I bavituximab monotherapy trial in advanced solid cancers is continuing.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in- house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio- manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking stat
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
2. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
3. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
5. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
6. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
7. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
8. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
9. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Patient engagement has become ... organizations are turning to an assortment of marketing ... part of this evolving approach to patient engagement, ... and engage patients throughout their experiences with a ... By mapping the patient journey and employing a ...
(Date:7/11/2014)... , July 11, 2014 Research and ... "Global and Chinese Medical X-ray Film Industry Report 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 Global And Chinese Medical ... in-depth study on the current state of the Global ... Chinese situation. The report provides a basic overview ...
(Date:7/11/2014)... 2014  Kindred Hospital Houston Northwest, with Wound ... of its new outpatient wound healing center.  The ... with chronic, hard to heal wounds. Chronic wounds ... amputation, lower leg wounds related to blood flow ... traumatic injury wounds which are complex and demonstrate ...
Breaking Medicine Technology:New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global and Chinese Medical X-ray Film Industry Report 2014 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2
... Mass. , Feb. 4 Recognizing that corporate ... they contain, Northern Light ( www.northernlight.com ) today announced that ... excess of $2 billion can be searched, analyzed ... been steadily increasing the number of market research sources integrated ...
... N.C. , Feb. 4 Gorbec Pharmaceutical ... prescription pharmaceutical products, is opening a GMP-compliant analytical laboratory ... expand Gorbec,s current services for analytical method development and ... its U.S. customer base as well as develop a ...
Cached Medicine Technology:Northern Light Surpasses $2 Billion Worth of Research Content Integrated Into SinglePoint Strategic Research Portals 2Northern Light Surpasses $2 Billion Worth of Research Content Integrated Into SinglePoint Strategic Research Portals 3Gorbec Pharmaceutical Services, Inc. Announces the Launch of Its GMP Analytical Laboratory in China 2
(Date:7/13/2014)... 2014 A Xarelto lawsuit webpage ... to provide consumers with the most current information regarding ... the blood-thinning medication, as well as the growing ... around the country. The law firm is now offering ... from life-threatening internal bleeding and related complications while using ...
(Date:7/13/2014)... July 13, 2014 According to The ... is a comprehensive program that teaches people how to ... neuropathy without medications. This program also provides people ... of peripheral neuropathy , including numbness, prickling, burning, and ... review that this home treatment program can help people ...
(Date:7/12/2014)... Recently, iFitDress.com, one of the world’s leading ... red evening gowns . What’s more, all these hot outfits ... The company’s senior spokesman states, “We are proud to announce ... is an enjoyable shopping experience. In addition to the big ... low prices do not always mean bad quality. All the ...
(Date:7/12/2014)... The report, "Phthalic Anhydride and Derivatives ... Application & Geography – Trends & Forecast to 2018," ... forecasting of market volume and value. The report also ... The market of phthalic anhydride is projected to grow ... million by 2018, with a CAGR of 5.24% from ...
(Date:7/12/2014)... The Security Analytics market is estimated to grow from ... at an expected CAGR of 9.7% for the period ... increasing number of security breaches, continued line of sophisticated ... organizations are enormous. Vendors in the security analytics market ... develop better and more secure systems. , There has ...
Breaking Medicine News(10 mins):Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:Discounted Red Evening Gown Announced by iFitDress.com 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4
... ,better for you, options; portion-controlled treats remain popular this ... ... Oct. 1 For the 93 percent of kids who will,trick-or-treat ... ever before, including more health-minded product options,available alongside the classic treats, ...
... ZURICH, Switzerland, October 1 , - Share Exchange Offer to ... & Johnson - ISIN: US4781601046 - Symbol: JNJ, The K&N ... every 1 Johnson & Johnson share a change into 1 share ... The offer period starts on 13th October 2008 and ends ...
... of almost 1,500 kidney cancer patients treated at Memorial ... as much kidney tissue as possible may improve overall ... at the time their cancer is diagnosed. The finding ... function appear to be increasing. , "In patients who ...
... is a fact that,Multi-Drug Resistant organisms are on ... medicines. According to the World Health Organization,(WHO) these ... and mortality rates, which has led to a ... safe, natural and,complementary solutions to this growing problem., ...
... says physicians have unique opportunity to help parents and ... ... Washington, DC (Vocus) October 1, 2008 ... their families understand the http://www.childrensnational.org/?utm_source=pressrelease&utm_medium=9_30&utm_campaign=driving_safety [importance of responsible driving], ...
... on the horizon, dentists, ,as well as all other medical practitioners, ... Flasch, of Flasch Business Expansion. An award winning consultant with over ... expand their practices using precise business strategies. , ... ...
Cached Medicine News:Health News:Latest Trick-or-Treats Give You Something Good to Eat 2Health News:Latest Trick-or-Treats Give You Something Good to Eat 3Health News:Latest Trick-or-Treats Give You Something Good to Eat 4Health News:Research suggests doctors should consider kidney-sparing surgery 2Health News:Research suggests doctors should consider kidney-sparing surgery 3Health News:Argentyn 23(R) Homeopathic First Aid Gel - Another World's First by Natural-Immunogenics Corp. for Healthcare Professionals 2Health News:Healthcare Providers Can Help Reduce Teen Driving Deaths 2Health News:Healthcare Providers Can Help Reduce Teen Driving Deaths 3Health News:Medical Marketing Expert Offers Dentists Tips for Thriving Down Economy After the Wall Street Dilemma 2Health News:Medical Marketing Expert Offers Dentists Tips for Thriving Down Economy After the Wall Street Dilemma 3
With MediLive MindStream you can make, cut and edit digital videos, add commentaries and notes, and save them. MediLive MindStream - intuitive user interface and high-resolution monitor all in one....
... The VISUPAC system and the FF 450plus ... a unique level of accuracy and security ... or aftermarket configuration. Without this level of ... be assured.,Matching the VISUPAC system pixel for ...
... Monitor is the smartest, toughest and most ... an on-board artificial intelligence algorithm, DiogenesTM, the ... arrhythmias while on the patient. The Decipher ... all the rigorous tests required to monitor ...
... The Epicardia 4000 is a hospital-grade ... Epicardia software, Diogenes Arrhythmia and ST analysis ... supporting hardware and software. Facilities with an ... over running reports, customizing them to suit ...
Medicine Products: